flutamide has been researched along with Hyperandrogenism in 53 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-dose flutamide-metformin (Flu-Met) with an oral contraceptive is a therapeutic option for women with hyperinsulinaemic hyperandrogenism." | 9.12 | Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. ( de Zegher, F; Ibáñez, L; Valls, C, 2006) |
| "(i) A high leukocyte count is already present in girls with hyperinsulinaemic hyperandrogenism, and this is due to a raised neutrophil count; (ii) this hyperneutrophilia is attenuated by metformin or flutamide-metformin, and is amplified by OC monotherapy; (iii) if these treatments are combined, the normalizing effect of flutamide-metformin overcomes the OC effect on neutrophil count." | 9.11 | High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. ( de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, AM, 2005) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 9.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "Triptorelin, CPA, and flutamide are effective drugs for the treatment of hirsutism." | 9.09 | Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. ( Balsa, J; Escobar-Morreale, HF; Pazos, F; Sancho, JM; Varela, C, 1999) |
| " Flutamide, a nonsteroidal antiandrogen, is known to be effective in reducing hirsutism in patients with ovarian hyperandrogenism." | 9.09 | Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N, 2000) |
| "The aim of this work was to evaluate the efficacy of two new antiandrogen drugs, finasteride and flutamide, in 80 hirsute patients: 44 with Polycystic Ovary Syndrome (PCOS) and 36 with Idiopathic Hirsutism (IH)." | 9.08 | [Finasteride and flutamide in the treatment of hirsutism]. ( De Fusco, D; Falsetti, L; Rosina, B, 1997) |
| "We describe the case of a 26-year-old girl with amenorrhea and severe hirsutism who was treated with flutamide 250 mg/day and developed liver toxicity during therapy." | 7.75 | Hepatotoxicity during low-dose flutamide treatment for hirsutism. ( Castelo-Branco, C; Del Pino, M, 2009) |
| "The authors hope that flutamide could enter in the list of medicines normally used to treat the beauty flaws of policistic acne and to restore a hormonal order associated to an effective contraception." | 7.74 | [Low-dose flutamide in the treatment of hyperandrogenism in adolescents]. ( Borrielli, I; Dinatale, A; Dugo, C; Dugo, N; Fattori, A; Mastroeni, MT; Pizzo, A, 2008) |
| "Hyperinsulinemic hyperandrogenism is the core of polycystic ovary syndrome (PCOS), and, accordingly, low-dose flutamide-metformin proved so far to be a most effective approach to normalize the broad spectrum of PCOS anomalies in nonobese adolescents and young women." | 7.73 | Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women. ( de Zegher, F; Ibáñez, L, 2006) |
| "Ovarian hyperandrogenism is a common disorder often presenting post menarche with anovulatory oligomenorrhea and signs of androgen excess." | 6.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Flutamide treatment can efficiently ameliorate the hyperandrogenemia-induced the disorders in aspects of decidualization, angiogenesis and uNK cells, which further improve the poor endometrial receptivity in PCOS patients." | 5.51 | Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy. ( Gong, H; Kuang, H; Li, Y; Ling, Y; Liu, H; Qiao, B; Wu, W; Xu, J; Yang, B; Yu, D, 2019) |
| "Hyperandrogenism is a condition affecting 5-10% of adolescents." | 5.48 | Very low dose of flutamide in the treatment of hyperandrogenism. ( Canu, E; Fulghesu, AM; Melis, F; Melis, GB; Murru, G, 2018) |
| "Flutamide treatment decreases cortisol clearance, thereby prolonging its half-life." | 5.31 | Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ( Brook, CG; Charmandari, E; Hindmarsh, PC; Honour, JW; Johnston, A, 2002) |
| "Low-dose flutamide-metformin (Flu-Met) with an oral contraceptive is a therapeutic option for women with hyperinsulinaemic hyperandrogenism." | 5.12 | Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. ( de Zegher, F; Ibáñez, L; Valls, C, 2006) |
| "One of the treatments for hyperinsulinemic hyperandrogenism in nonobese women is combined androgen receptor blockade (with flutamide; Flu), insulin sensitization (with metformin; Met) plus an estroprogestagen contraceptive." | 5.12 | Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. ( de Zegher, F; del Rio, L; Enríquez, G; Ibáñez, L; López-Bermejo, A; Valls, C, 2007) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "(i) A high leukocyte count is already present in girls with hyperinsulinaemic hyperandrogenism, and this is due to a raised neutrophil count; (ii) this hyperneutrophilia is attenuated by metformin or flutamide-metformin, and is amplified by OC monotherapy; (iii) if these treatments are combined, the normalizing effect of flutamide-metformin overcomes the OC effect on neutrophil count." | 5.11 | High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. ( de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, AM, 2005) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "To compare the relative effectiveness of two newer antiandrogens (flutamide and finasteride) with cyproterone acetate (CPA), at both low and high doses in the treatment of moderate to severe acne in hyperandrogenic women." | 5.10 | A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. ( Carmina, E; Lobo, RA, 2002) |
| "Flutamide at a dose of 250 mg daily induced a modest improvement in alopecia after 1 year, whereas cyproterone acetate and finasteride were not effective." | 5.10 | Treatment of hyperandrogenic alopecia in women. ( Carmina, E; Lobo, RA, 2003) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 5.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "Finasteride, CPA, and flutamide are equally effective in decreasing hirsutism, despite different mechanisms of action." | 5.09 | Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. ( Bersi, C; Fruzzetti, F; Genazzani, AR; Parrini, D; Ricci, C, 1999) |
| "Triptorelin, CPA, and flutamide are effective drugs for the treatment of hirsutism." | 5.09 | Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. ( Balsa, J; Escobar-Morreale, HF; Pazos, F; Sancho, JM; Varela, C, 1999) |
| " Flutamide, a nonsteroidal antiandrogen, is known to be effective in reducing hirsutism in patients with ovarian hyperandrogenism." | 5.09 | Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N, 2000) |
| "The aim of this work was to evaluate the efficacy of two new antiandrogen drugs, finasteride and flutamide, in 80 hirsute patients: 44 with Polycystic Ovary Syndrome (PCOS) and 36 with Idiopathic Hirsutism (IH)." | 5.08 | [Finasteride and flutamide in the treatment of hirsutism]. ( De Fusco, D; Falsetti, L; Rosina, B, 1997) |
| "Patients under flutamide therapy showed significant improvements in hirsutism scores after 6 months of treatment with a maximum effect at 12 months that was maintained during all the therapy time." | 3.83 | Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women. ( Alvarez-Olivares, L; Balasch, J; Castelo-Branco, C; Hernández-Angeles, C, 2016) |
| "We describe the case of a 26-year-old girl with amenorrhea and severe hirsutism who was treated with flutamide 250 mg/day and developed liver toxicity during therapy." | 3.75 | Hepatotoxicity during low-dose flutamide treatment for hirsutism. ( Castelo-Branco, C; Del Pino, M, 2009) |
| "The authors hope that flutamide could enter in the list of medicines normally used to treat the beauty flaws of policistic acne and to restore a hormonal order associated to an effective contraception." | 3.74 | [Low-dose flutamide in the treatment of hyperandrogenism in adolescents]. ( Borrielli, I; Dinatale, A; Dugo, C; Dugo, N; Fattori, A; Mastroeni, MT; Pizzo, A, 2008) |
| "Hyperinsulinemic hyperandrogenism is the core of polycystic ovary syndrome (PCOS), and, accordingly, low-dose flutamide-metformin proved so far to be a most effective approach to normalize the broad spectrum of PCOS anomalies in nonobese adolescents and young women." | 3.73 | Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women. ( de Zegher, F; Ibáñez, L, 2006) |
| "Ovarian hyperandrogenism is a common disorder often presenting post menarche with anovulatory oligomenorrhea and signs of androgen excess." | 2.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "We hypothesized that dyslipidemia and anovulation in nonobese women with polycystic ovary syndrome are essentially secondary to the concerted effects of hyperandrogenism and insulin resistance." | 2.70 | Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. ( De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C, 2002) |
| "Hirsutism is a common disorder with a major impact on quality of life." | 2.53 | Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. ( Fedorowicz, Z; van Zuuren, EJ, 2016) |
| "While the treatment of hyperandrogenism makes use of different drugs already studied, the debate about the use of insulin sensitizing drugs is still open." | 2.42 | Which treatment options should be used in adolescents with polycystic ovary syndrome? ( Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P, 2004) |
| "Flutamide treatment can efficiently ameliorate the hyperandrogenemia-induced the disorders in aspects of decidualization, angiogenesis and uNK cells, which further improve the poor endometrial receptivity in PCOS patients." | 1.51 | Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy. ( Gong, H; Kuang, H; Li, Y; Ling, Y; Liu, H; Qiao, B; Wu, W; Xu, J; Yang, B; Yu, D, 2019) |
| "Hyperandrogenism is a condition affecting 5-10% of adolescents." | 1.48 | Very low dose of flutamide in the treatment of hyperandrogenism. ( Canu, E; Fulghesu, AM; Melis, F; Melis, GB; Murru, G, 2018) |
| "Flutamide was used in the present study as it blocks the effects of the androgen receptor." | 1.46 | The role of fructose‑1,6‑bisphosphatase 1 in abnormal development of ovarian follicles caused by high testosterone concentration. ( Gao, F; Gao, Y; Liu, H; Liu, T; Mu, X; Shu, X; Wang, J; Zhao, H, 2017) |
| "Hirsutism affects 5-8% of the whole female population." | 1.39 | Hirsutism - from diagnosis to use of antiandrogens. ( Karaca, Z; Kelestimur, F; Unluhizarci, K, 2013) |
| "Flutamide is a pure non-steroidal anti-androgen that may be hepatotoxic, when given in high-dose (750 mg/d)." | 1.33 | Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. ( de Zegher, F; Ferrer, A; Ibáñez, L; Jaramillo, A, 2005) |
| "Flutamide treatment decreases cortisol clearance, thereby prolonging its half-life." | 1.31 | Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ( Brook, CG; Charmandari, E; Hindmarsh, PC; Honour, JW; Johnston, A, 2002) |
| "Flutamide was administered to seven hyperandrogenaemic women and five normal cycling women, at a dose of 250 mg on the evening of day 1, followed by daily doses of 750 mg for 6 days." | 1.29 | The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. ( Rabenbauer, B; Sir-Petermann, T; Wildt, L, 1993) |
| "Insulin resistance was observed in both ovarian and nonovarian hyperandrogenism, as distinguished by acute GnRH agonist testing." | 1.29 | The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. ( Brun, E; Caputo, M; Castello, R; Furlani, L; Magnani, CM; Moghetti, P; Muggeo, M; Negri, C; Tosi, F, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (13.21) | 18.2507 |
| 2000's | 23 (43.40) | 29.6817 |
| 2010's | 21 (39.62) | 24.3611 |
| 2020's | 2 (3.77) | 2.80 |
| Authors | Studies |
|---|---|
| Abdalla, MA | 1 |
| Shah, N | 1 |
| Deshmukh, H | 1 |
| Sahebkar, A | 1 |
| Östlundh, L | 1 |
| Al-Rifai, RH | 1 |
| Atkin, SL | 1 |
| Sathyapalan, T | 1 |
| Landers, RSM | 1 |
| Padmanabhan, V | 1 |
| Cardoso, RC | 1 |
| Liu, T | 1 |
| Zhao, H | 1 |
| Wang, J | 1 |
| Shu, X | 1 |
| Gao, Y | 1 |
| Mu, X | 1 |
| Gao, F | 1 |
| Liu, H | 2 |
| Fulghesu, AM | 2 |
| Melis, F | 1 |
| Murru, G | 1 |
| Canu, E | 1 |
| Melis, GB | 1 |
| Gong, H | 1 |
| Wu, W | 1 |
| Xu, J | 1 |
| Yu, D | 1 |
| Qiao, B | 1 |
| Yang, B | 1 |
| Li, Y | 1 |
| Ling, Y | 1 |
| Kuang, H | 1 |
| Unluhizarci, K | 1 |
| Karaca, Z | 1 |
| Kelestimur, F | 1 |
| Ibáñez, L | 22 |
| Ong, KK | 2 |
| López-Bermejo, A | 7 |
| Dunger, DB | 3 |
| de Zegher, F | 21 |
| Blesson, CS | 1 |
| Chinnathambi, V | 1 |
| Hankins, GD | 1 |
| Yallampalli, C | 1 |
| Sathishkumar, K | 1 |
| Bettoli, V | 1 |
| Zauli, S | 1 |
| Virgili, A | 1 |
| Yang, F | 1 |
| Ruan, YC | 1 |
| Yang, YJ | 1 |
| Wang, K | 1 |
| Liang, SS | 1 |
| Han, YB | 1 |
| Teng, XM | 1 |
| Yang, JZ | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 1 |
| Osol, G | 1 |
| Díaz, M | 6 |
| Gallego-Escuredo, JM | 1 |
| Villarroya, F | 1 |
| van Zuuren, EJ | 1 |
| Fedorowicz, Z | 1 |
| Castelo-Branco, C | 2 |
| Hernández-Angeles, C | 1 |
| Alvarez-Olivares, L | 1 |
| Balasch, J | 1 |
| Pizzo, A | 1 |
| Borrielli, I | 1 |
| Mastroeni, MT | 1 |
| Fattori, A | 1 |
| Dugo, C | 1 |
| Dugo, N | 1 |
| Dinatale, A | 1 |
| Del Pino, M | 1 |
| Bachelot, A | 1 |
| Chabbert-Buffet, N | 1 |
| Salenave, S | 1 |
| Kerlan, V | 1 |
| Galand-Portier, MB | 1 |
| Lázaro, I | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Sebastiani, G | 1 |
| Sánchez-Infantes, D | 1 |
| Salvador, C | 2 |
| Chacón, MR | 1 |
| Maymó-Masip, E | 1 |
| Vendrell, J | 1 |
| Bruni, V | 1 |
| Peruzzi, E | 1 |
| Dei, M | 1 |
| Nannini, S | 1 |
| Seravalli, V | 1 |
| Sisti, G | 1 |
| Fambrini, M | 1 |
| Karaahmet, F | 1 |
| Kurt, K | 1 |
| Xue, K | 1 |
| Liu, JY | 1 |
| Murphy, BD | 1 |
| Tsang, BK | 1 |
| Carmina, E | 2 |
| Lobo, RA | 2 |
| Ong, K | 2 |
| Ferrer, A | 4 |
| Amin, R | 1 |
| Dunger, D | 1 |
| Villa, P | 1 |
| Di Sebastiano, F | 1 |
| Rossodivita, A | 1 |
| Sagnella, F | 1 |
| Barini, A | 1 |
| Lanzone, A | 1 |
| Valls, C | 5 |
| Cabré, S | 1 |
| Jaramillo, A | 1 |
| Jaramillo, AM | 1 |
| Moghetti, P | 2 |
| Legro, RS | 1 |
| del Rio, L | 1 |
| Enríquez, G | 2 |
| Sir-Petermann, T | 1 |
| Rabenbauer, B | 1 |
| Wildt, L | 1 |
| Tosi, F | 1 |
| Castello, R | 1 |
| Magnani, CM | 1 |
| Negri, C | 1 |
| Brun, E | 1 |
| Furlani, L | 1 |
| Caputo, M | 1 |
| Muggeo, M | 1 |
| Zemtsov, A | 1 |
| Wilson, L | 1 |
| Falsetti, L | 1 |
| De Fusco, D | 1 |
| Rosina, B | 1 |
| Pazos, F | 1 |
| Escobar-Morreale, HF | 1 |
| Balsa, J | 1 |
| Sancho, JM | 1 |
| Varela, C | 1 |
| Fruzzetti, F | 1 |
| Bersi, C | 1 |
| Parrini, D | 1 |
| Ricci, C | 1 |
| Genazzani, AR | 1 |
| Prezelj, J | 1 |
| Kocijancic, A | 1 |
| Potau, N | 1 |
| Marcos, MV | 1 |
| Charmandari, E | 1 |
| Johnston, A | 1 |
| Honour, JW | 1 |
| Brook, CG | 1 |
| Hindmarsh, PC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for flutamide and Hyperandrogenism
| Article | Year |
|---|---|
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.
Topics: Androgens; Dexamethasone; Female; Flutamide; Humans; Hyperandrogenism; Metformin; Polycystic Ovary S | 2023 |
Is hormonal treatment still an option in acne today?
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; | 2015 |
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2016 |
Anti-androgen treatments.
Topics: Androgen Antagonists; Cyproterone Acetate; Estrogens; Female; Finasteride; Flutamide; Gonadotropin-R | 2010 |
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; H | 2004 |
23 trials available for flutamide and Hyperandrogenism
| Article | Year |
|---|---|
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac | 2016 |
Divergent effects of ethinylestradiol-drospirenone and flutamide-metformin on follistatin in adolescents and women with hyperinsulinemic androgen excess.
Topics: Adolescent; Androgen Antagonists; Androstenes; Body Composition; Contraceptives, Oral, Hormonal; Eth | 2011 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Body Composition; Cyproterone Acetate; Drug Combina | 2011 |
Ethinyl estradiol-cyproterone acetate versus low-dose pioglitazone-flutamide-metformin for adolescent girls with androgen excess: divergent effects on CD163, TWEAK receptor, ANGPTL4, and LEPTIN expression in subcutaneous adipose tissue.
Topics: Abdominal Fat; Adolescent; Androgen Antagonists; Angiopoietin-Like Protein 4; Angiopoietins; Antigen | 2012 |
A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Administration Schedule; Femal | 2002 |
Treatment of hyperandrogenic alopecia in women.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Androgen Antagonists; Cyproterone Acetate; Dehydroepi | 2003 |
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug; | 2003 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2003 |
Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Contraceptive Ag | 2003 |
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Androstenes; Drug Therapy, Com | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Fema | 2005 |
High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception.
Topics: Adolescent; Adult; Androgen Antagonists; Child; Contraceptives, Oral; Drug Therapy, Combination; Fem | 2005 |
Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.
Topics: Administration, Cutaneous; Adolescent; Adult; C-Reactive Protein; Contraceptive Agents, Female; Cont | 2006 |
Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess.
Topics: Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Body Composition; Body Mass Index; Carotid | 2007 |
Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype.
Topics: Adolescent; Age Factors; Child; Cross-Over Studies; Drug Therapy, Combination; Female; Flutamide; Ge | 2007 |
Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Topics: Adiponectin; Adolescent; Adult; Double-Blind Method; Female; Flutamide; Humans; Hyperandrogenism; Hy | 2008 |
[Finasteride and flutamide in the treatment of hirsutism].
Topics: Administration, Oral; Adult; Androgen Antagonists; Dose-Response Relationship, Drug; Female; Finaste | 1997 |
Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.
Topics: Adult; Androgen Antagonists; Body Mass Index; Contraceptives, Oral, Hormonal; Cyproterone Acetate; D | 1999 |
Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsut | 1999 |
Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
Topics: Adolescent; Androgen Antagonists; Blood Glucose; Female; Flutamide; Glucose Tolerance Test; Hirsutis | 2000 |
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandroge | 2002 |
25 other studies available for flutamide and Hyperandrogenism
| Article | Year |
|---|---|
Developmental programming: gestational testosterone excess disrupts LH secretion in the female sheep fetus.
Topics: Animals; Female; Fetal Development; Fetus; Flutamide; Hyperandrogenism; Luteinizing Hormone; Polycys | 2020 |
The role of fructose‑1,6‑bisphosphatase 1 in abnormal development of ovarian follicles caused by high testosterone concentration.
Topics: Androgen Antagonists; Animals; Female; Flutamide; Forkhead Box Protein O1; Fructose-Bisphosphatase; | 2017 |
Very low dose of flutamide in the treatment of hyperandrogenism.
Topics: Acne Vulgaris; Adolescent; Androgen Antagonists; Androstenes; Dose-Response Relationship, Drug; Drug | 2018 |
Flutamide ameliorates uterine decidualization and angiogenesis in the mouse hyperandrogenemia model during mid-pregnancy.
Topics: Androgen Antagonists; Animals; Decidua; Disease Models, Animal; Embryo Implantation; Female; Flutami | 2019 |
Hirsutism - from diagnosis to use of antiandrogens.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; H | 2013 |
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |
Prenatal testosterone exposure induces hypertension in adult females via androgen receptor-dependent protein kinase Cδ-mediated mechanism.
Topics: Animals; Blood Pressure; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; | 2015 |
Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women.
Topics: Adult; Androgen Antagonists; Aromatase; Cell Line; Down-Regulation; Female; Fertilization in Vitro; | 2015 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women.
Topics: Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Flut | 2016 |
[Low-dose flutamide in the treatment of hyperandrogenism in adolescents].
Topics: Acne Vulgaris; Adolescent; Androgen Antagonists; Body Mass Index; Child; Female; Flutamide; Follow-U | 2008 |
Hepatotoxicity during low-dose flutamide treatment for hirsutism.
Topics: Adult; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Female; Flutamide; Hirsutism; H | 2009 |
Flutamide for androgen excess: low dose is best.
Topics: Adolescent; Androgen Antagonists; Female; Flutamide; Humans; Hyperandrogenism; Young Adult | 2011 |
Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females.
Topics: Adolescent; Adult; Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Biomarke | 2012 |
Hepatotoxicity with flutamide.
Topics: Androgen Antagonists; Chemical and Drug Induced Liver Injury; Female; Flutamide; Humans; Hyperandrog | 2012 |
Orphan nuclear receptor NR4A1 is a negative regulator of DHT-induced rat preantral follicular growth.
Topics: Androgens; Animals; Cells, Cultured; Cyclin D2; Dihydrotestosterone; Down-Regulation; Female; Flutam | 2012 |
Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women.
Topics: Adolescent; Adult; Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Biomarke | 2005 |
Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women.
Topics: Adolescent; Adult; Androgen Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination | 2006 |
Use of antiandrogens as therapy for women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Female; Flutamide; Humans; Hyperandrogenism; Polycystic Ovary Syndrome | 2006 |
Long-term, low-dose flutamide does not cause hepatotoxicity in hyperandrogenic women.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Flutamide; Humans; Hyperandrogenism; Liver; Liver F | 2006 |
The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women.
Topics: Adolescent; Adult; Androgens; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfat | 1993 |
The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
Topics: Adult; Androgen Antagonists; Androgens; Buserelin; Female; Flutamide; Glucose Clamp Technique; Human | 1996 |
Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy.
Topics: Acanthosis Nigricans; Adolescent; Androgen Antagonists; Contraceptives, Oral, Combined; Contraceptiv | 1997 |
Comment on spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Female; Flutamide; Gonadotropin-Releasing Hormone; Humans; Hyperandrogenism; Osteoporosis; Spironola | 1999 |
Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia.
Topics: Adolescent; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Anti-Inflammatory Agents; Area Un | 2002 |